2017
DOI: 10.1007/s13770-016-0017-y
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression

Abstract: To evaluate whether Palmitoyl-pentapeptide (Pal-KTTKS), a lipidated subfragment of type 1 pro-collagen (residues 212-216), plays a role in fibroblast contractility, the effect of Pal-KTTKS on the expression of pro-fibrotic mediators in hypertropic scarring were investigated in relation with trans-differentiation of fibroblast to myofibroblast, an icon of scar formation. a-SMA was visualized by immunofluorescence confocal microscopy with a Cy-3-conjugated monoclonal antibody. The extent of a-SMA-positive fibrob… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
8
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 27 publications
0
8
0
Order By: Relevance
“…In view of the above, we hypothesized that the conjugation of a collagenesis-inducing, or collagen-boosting peptide (CBP) to an AMP known to be active against both Gram-positive and Gram-negative bacteria might produce dual-action peptide chimeras retaining the properties of their parent CBP and AMP motifs, hence, with potential interest for the management of cSSTI. To this end, the CBP chosen was the matrikine-like peptide KTTKS, also known as “pentapeptide-4” (ahead abbreviated to PP4) whose palmitoylated form (ahead abbreviated to C 16 -PP4) is widely used as a cosmeceutical known as “Matrixyl” (Jones et al, 2013; Choi et al, 2014; Aldag et al, 2016; Schagen, 2017) and reported to possess tissue regenerative properties (Tsai et al, 2007; Park et al, 2017; Krishnamoorthy et al, 2018). As the AMP motif, we chose a previously de novo designed synthetic peptide, named 3.1, earlier reported as highly active against both Gram-positive and Gram-negative bacteria (Kang et al, 2009).…”
Section: Introductionmentioning
confidence: 99%
“…In view of the above, we hypothesized that the conjugation of a collagenesis-inducing, or collagen-boosting peptide (CBP) to an AMP known to be active against both Gram-positive and Gram-negative bacteria might produce dual-action peptide chimeras retaining the properties of their parent CBP and AMP motifs, hence, with potential interest for the management of cSSTI. To this end, the CBP chosen was the matrikine-like peptide KTTKS, also known as “pentapeptide-4” (ahead abbreviated to PP4) whose palmitoylated form (ahead abbreviated to C 16 -PP4) is widely used as a cosmeceutical known as “Matrixyl” (Jones et al, 2013; Choi et al, 2014; Aldag et al, 2016; Schagen, 2017) and reported to possess tissue regenerative properties (Tsai et al, 2007; Park et al, 2017; Krishnamoorthy et al, 2018). As the AMP motif, we chose a previously de novo designed synthetic peptide, named 3.1, earlier reported as highly active against both Gram-positive and Gram-negative bacteria (Kang et al, 2009).…”
Section: Introductionmentioning
confidence: 99%
“…(ii) negative vesicles might increase the retention of encapsulated lipophilic molecules in the skin, and the improvement of drug retention in negative vesicles might be related to the ability of these vesicles to promote structural changes in the deep layer of the skin, facilitating drug retention into the skin (Ogiso et al., 2001 ; Maione-Silva et al., 2019 ). (iii) as a signal peptide in skin tissue, KTTKS could be recognized and bound by signal recognition particles (SRP) in skin tissues, resulting in the retention of KTTKS modified ethosomes in the skin (Tang et al., 2013 ; Park et al., 2017 ). In conclusion, IMC-KTTKS-Es gel could increase the intradermal retention of drugs and reduce the number of drugs entering the systemic circulation, and these characteristics are expected to increase the curative effect and reduce the risk of increasing systemic toxicity when used in the treatment of local skin diseases.…”
Section: Resultsmentioning
confidence: 99%
“…Therefore, it was suggested to consider palmitoyl-pentapeptide as a therapeutic agent in the prevention of scar lesions. 13 …”
Section: Introductionmentioning
confidence: 99%